Evidence map›Paper›PMID 42161414›Full record

ArticleRMD open2026

PD1

Samuel Bitoun, Matthieu Roulleaux-Dugage, Marie Naigeon, Caroline de Oliveira, Caroline Berthot, Xavier Mariette, Gaetane Nocturne, Nathalie Chaput

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Samuel BitounRheumatology Department, Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), CEA, FHU CARE 2, Le Kremlin-Bicêtre, France.ORCID 0000-0003-0891-2269
Matthieu Roulleaux-DugageLaboratoire d'Immunomonitoing en Oncologie US23, Biothérapies Innovantes U1363, Université Paris-Saclay, Gustave Roussy, INSERM, Villejuif, France.
Marie NaigeonLaboratoire d'Immunomonitoing en Oncologie US23, Biothérapies Innovantes U1363, Université Paris-Saclay, Gustave Roussy, INSERM, Villejuif, France.
Caroline de OliveiraLaboratoire d'Immunomonitoing en Oncologie US23, Biothérapies Innovantes U1363, Université Paris-Saclay, Gustave Roussy, INSERM, Villejuif, France.ORCID 0009-0009-9922-607X
Caroline BerthotLaboratoire d'Immunomonitoing en Oncologie US23, Biothérapies Innovantes U1363, Université Paris-Saclay, Gustave Roussy, INSERM, Villejuif, France.
Xavier MarietteRheumatology Department, Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), CEA, FHU CARE 2, Le Kremlin-Bicêtre, France.ORCID 0000-0002-4244-5417
Gaetane NocturneRheumatology Department, Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), CEA, FHU CARE 2, Le Kremlin-Bicêtre, France.ORCID 0000-0001-6809-0733
Nathalie ChaputLaboratoire d'Immunomonitoing en Oncologie US23, Biothérapies Innovantes U1363, Université Paris-Saclay, Gustave Roussy, INSERM, Villejuif, France nathalie.chaput@gustaveroussy.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProgrammed cell death protein 1 (PD-1) and T cell immunoreceptor with Ig and ITIM domains (TIGIT) are immune checkpoints expressed on T cells. Despite recent development of PD-1 agonists in rheumatoid arthritis (RA), little is known about PD-1 and TIGIT coexpression in RA and other immune-mediated inflammatory diseases (IMIDs). This study quantified PD-1 and TIGIT expression in CD4 and CD8 T cells in patients with IMID and examined associations with disease characteristics and anti-tumour necrosis factor (TNF) response.

methodsBiologics-naïve patients with RA and spondyloarthritis (AS) were followed prospectively to assess anti-TNF response at 12 months. Sjögren's disease (SjD) patients and healthy volunteers (HV) were also included at baseline. PD-1 and TIGIT expression on CD4 and CD8 T cells was analysed by flow cytometry at baseline and after 3 months of anti-TNF treatment. Plasma cytokines were quantified using the Meso Scale Discovery assay.

results67 patients were included. Median CD8

conclusionCD8

Indexed as

Arthritis, RheumatoidCD4-Positive T-LymphocytesProgrammed Cell Death 1 ReceptorReceptors, ImmunologicSpondylarthritisTumor Necrosis Factor InhibitorsAdultBiomarkersCD8-Positive T-LymphocytesCytokinesFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeBiomarkersCytokinesPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, ImmunologicTIGIT protein, humanTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAnti-TNFRheumatoid ArthritisSpondyloarthritisT Cells

Identifiers

PMID42161414
PMCPMC13201991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.